iBio, Inc. - IBIO
About Gravity Analytica
Recent News
- 05.07.2025 - A Bet that Myostatins Can Muscle Out Obesity
- 05.05.2025 - iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
- 05.05.2025 - iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
- 05.02.2025 - iBio Reports Fiscal Third Quarter 2025 Financial Results
- 05.02.2025 - iBio Reports Fiscal Third Quarter 2025 Financial Results
- 04.29.2025 - iBio Raises $6.2 Million Through Warrant Inducement Transaction
- 04.29.2025 - iBio Raises $6.2 Million Through Warrant Inducement Transaction
- 04.22.2025 - iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
- 04.22.2025 - iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
- 04.21.2025 - AI-Powered Antibody Drug Discovery for Obesity and Cardiometabolic Diseases with Martin Brenner iBio
Recent Filings
- 05.07.2025 - D Notice of Exempt Offering of Securities
- 05.02.2025 - 8-K Current report
- 05.02.2025 - EX-99.1 EX-99.1
- 05.02.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
- 04.30.2025 - 424B5 Prospectus [Rule 424(b)(5)]
- 04.30.2025 - 424B5 Prospectus [Rule 424(b)(5)]
- 04.30.2025 - 424B5 Prospectus [Rule 424(b)(5)]
- 04.22.2025 - 8-K Current report
- 04.22.2025 - EX-99.1 EX-99.1
- 04.08.2025 - 8-K Current report